CRBP
Corbus Pharmaceuticals Holdings, Inc.
Healthcare — Biotechnology
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Strong Buy
1.1 / 5
10 analysts
$6.34
$-0.48 (-7.04%)
Target:
$35.30
(456.8%)
Price History
52-Week Range
Sign in to add CRBP to a watchlist or set price alerts.
Fundamentals
| Market Cap | $168.05M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.79 |
| EPS (TTM) | $-5.74 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -66.70% |
| Debt/Equity | 0.95 |
| Recommendation | Strong Buy 1.1 |
| Analyst Target | $35.30 |
| Analysts | 10 |
| Next Earnings | Aug 6, 2026 BMO |
| Indexes | - |
Technical Indicators
| RSI (14) | 69.9 |
| Beta | 2.59 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $20.56 |
| 52-Week Low | $7.12 |
| 50-Day Avg | $9.29 |
| 200-Day Avg | $10.19 |
| Avg Volume | 489.6K |
| Volume | 436.0K |
Performance Analysis
BULLISHCRBP shows predominantly bullish signals based on its fundamentals and technicals.
+
Trading near its 52-week low ($7.12), which could present a value opportunity.
+
RSI at 69.9 shows positive momentum.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
+
Wall Street consensus is "Strong Buy" from 10 analysts.
+
Average analyst target of $35.30 implies 456.8% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:04 UTC
Back to Screener Export Report